T Cell-Engaging Therapy for Solid Tumors.

T Cell-Engaging Therapy for Solid Tumors.
Clin Cancer Res. 2020 Oct 20;:
Authors: de Miguel M, Umana P, Gomes de Morais AL, Moreno V, Calvo E
Abstract
T cell-engagers are a rapidly evolving novel group of treatments that have in common the concurrent engagement of a T cell-surface molecule and a tumoral cell antigen. Bispecific antibodies and genetically engineered adoptive cell therapies, as chimeric antigen receptor or T cell receptor T cells, have similarities and differences among their mechanisms of action, toxicity profiles, and resistance pathways. Nevertheless, the success observed in the hematological field has not been obtained with solid tumors yet, as they are biologically more complex and have few truly tumor-specific cell surface antigens that can be targeted with high avidity T cells. Different strategies are under study to improve their short-term perspective, such as new generations of more active T cell-engagers, multi-target or combination of different treatments approaches, or to improve the manufacturing processes. A comprehensive review of T cell-engagers as a grouped treatment class, current status, and research directions in their application to solid tumors therapeutics are discussed here.
PMID: 33082210 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - October 20, 2020 Category: Cancer & Oncology Authors: de Miguel M, Umana P, Gomes de Morais AL, Moreno V, Calvo E Tags: Clin Cancer Res Source Type: research